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APOBEC3G (A3G) is a member of the cellular polynucleotide cytidine deaminases,
which catalyze the deamination of cytosine (dC) to uracil (dU) in single-stranded
DNA. These enzymes potently inhibit the replication of a variety of retroviruses and
retrotransposons, including HIV-1. A3G is incorporated into vif-deficient HIV-1 virions
and targets viral reverse transcripts, particularly minus-stranded DNA products, in newly
infected cells. It is well established that the enzymatic activity of A3G is closely correlated
with the potential to greatly inhibit HIV-1 replication in the absence of Vif. However,
the details of the underlying molecular mechanisms are not fully understood. One
potential mechanism of A3G antiviral activity is that the A3G-dependent deamination
may trigger degradation of the dU-containing reverse transcripts by cellular uracil DNA
glycosylases (UDGs). More recently, another mechanism has been suggested, in which
the virion-incorporated A3G generates lethal levels of the G-to-A hypermutation in
the viral DNA genome, thus potentially driving the viruses into “error catastrophe”
mode. In this mini review article, we summarize the deaminase-dependent and
deaminase-independent molecular mechanisms of A3G and discuss how A3G-
mediated deamination is linked to antiviral mechanisms.
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INTRODUCTION
The human apolipoprotein B mRNA editing enzyme catalytic subunit 3 (A3) family of cellular
polynucleotide cytidine deaminases comprises seven members (A, B, C, D, F, G, and H) that
catalyze the conversion of cytosine (dC) to uracil (dU) on single-stranded DNA (ssDNA;
Kitamura et al., 2011). These enzymes, particularly A3G, exhibit potent antiviral activity against
retrotransposons and retroviruses, including HIV-1 (Sheehy et al., 2002; Simon et al., 2005; Bogerd
et al., 2006; Muckenfuss et al., 2006; Okeoma et al., 2007; Hultquist et al., 2011; Chaipan et al.,
2013). However, the HIV-1 accessory protein viral infectivity factor (Vif), antagonizes the A3G-
mediated host defense system, thereby promoting the propagation of HIV-1 in human cells (Sheehy
et al., 2002; Conticello et al., 2003). Vif recruits A3G into the E3 ubiquitin ligase complex, including
Cullin5, ElonginB/C, and core binding factor subunit beta (CBFβ), and promotes A3G degradation
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through the ubiquitin-proteasome pathway (Yu et al., 2003; Yu
Y. et al., 2004; Salter et al., 2012; Guo et al., 2014). Thus, in
the absence of Vif, A3G is incorporated into HIV-1 virions
from their viral producers and exerts its antiviral activity in
newly infected cells (Sheehy et al., 2002; Anderson and Hope,
2008). The A3G incorporation depends on its binding affinity
to the viral nucleocapsid (NC) domain of Gag and/or to
the viral/non-viral RNAs (Cen et al., 2004; Luo et al., 2004;
Svarovskaia et al., 2004; Burnett and Spearman, 2007; Strebel
and Khan, 2008; Apolonia et al., 2015; York et al., 2016). In
infected cells, A3G inhibits viral replication through the specific
deamination of dCs in viral minus-strand DNA, thus resulting
in massive G-to-A hypermutation of the nascent viral DNA
(vDNA) genome during reverse transcription (Lecossier et al.,
2003; Zhang et al., 2003; Suspene et al., 2004). The A3G-
induced hypermutation is observed as a discrete “all or nothing”
phenomenon (Armitage et al., 2012). In addition, A3G directly
blocks reverse transcriptase (RT) elongation in a deaminase-
independent manner (Guo et al., 2006, 2007; Iwatani et al.,
2007; Bishop et al., 2008; Gillick et al., 2013; Chaurasiya et al.,
2014) and interferes with the integration of proviral DNA into
the host chromosome (Luo et al., 2007; Mbisa et al., 2007,
2010). These cooperative molecular mechanisms are likely to
be important in maximizing the anti-HIV-1 activity of A3G.
Nevertheless, several studies have shown that the enzymatic
activity of A3G is closely correlated with the potential to
highly inhibit vif -deficient HIV-1 replication (Mangeat et al.,
2003; Navarro et al., 2005; Iwatani et al., 2006; Browne et al.,
2009). In contrast to understanding of deaminase-independent
mechanisms, the details of deaminase-dependent mechanisms, in
which A3G inhibits vif -deficient HIV-1 replication, are not fully
understood.
Unique Features of A3G-Mediated
Deamination
The N-terminal and C-terminal domains (NTD and CTD,
respectively) of A3G both contain Zn coordinate motifs
((H/C)xE(x)23−28PCxxC; Wedekind et al., 2003; Conticello et al.,
2005). The A3G CTD is catalytically active, whereas its NTD
has no enzymatic activity but exhibits strong binding to ssDNA
and RNA (Hache et al., 2005; Navarro et al., 2005; Iwatani
et al., 2006). During the reverse transcription of vif -deficient
HIV-1, A3G preferentially deaminates the second dC of 5′-CC
dinucleotide sites in the newly synthesized viral minus-stranded
ssDNA (Harris et al., 2003; Mangeat et al., 2003; Zhang et al.,
2003; Yu Q. et al., 2004). This dinucleotide preference is unique
among A3 family proteins (Hultquist et al., 2011; Rathore
et al., 2013). This deamination occurs more efficiently at the
dC close to the 5′-end of ssDNA and less efficiently at the
last ∼30 nt of the 3′ ssDNA end, the so-called dead zone
(Chelico et al., 2006, 2008). Therefore, it is likely that A3G more
efficiently catalyzes the deamination of ssDNA when the A3G
CTD is oriented toward the 5′ ssDNA end, and the A3G NTD
restricts access of the CTD to the dead zone (Chelico et al.,
2010; Shlyakhtenko et al., 2015). Furthermore, the deamination
efficacy decreases with decreasing ssDNA length (Chelico et al.,
2006), thus probably reflecting the infrequent orientation of





APOBEC3G deaminase activity is crucial for its antiviral activity
and restriction of vif -deficient HIV-1 replication (Mangeat et al.,
2003; Navarro et al., 2005; Iwatani et al., 2006; Browne et al.,
2009). An experimental-mathematical study estimated that 99.3%
of the antiviral effect of A3G is dependent on its deaminase
activity (Kobayashi et al., 2014) (Figure 1). Many reports have
consistently supported the presumable deaminase-dependent
mechanism in which massive A3G-mediated hypermutations
in viral reverse transcripts cause lethal mutational loads that
terminate progeny virus production and subsequent virus
propagation (Harris et al., 2003; Lecossier et al., 2003; Mangeat
et al., 2003; Zhang et al., 2003; Suspene et al., 2004; Rawson
et al., 2015). This mechanism has previously been described as
the error catastrophe mechanism (Crotty et al., 2001; Eigen, 2002;
Graci and Cameron, 2002). The mutations introduced in the viral
genome, to a certain threshold, lead to sequence diversification,
thus enabling adaptation to environmental changes. In contrast,
massive amounts of mutations caused by mutagens lead to
viral replication failure, called error catastrophe. A3G excessively
converts dC to dU in the vDNA of vif -deficient HIV-1, thus
resulting in G-to-A hypermutations in the viral integrated
genomes. These mutations include substitutions of tryptophan
codons to in-frame premature stop codons and/or may introduce
amino acid changes lethal for viral replication. A3G probably
hinders functional viral protein expression and progeny virus
production (Pace et al., 2006) (Figure 1). A recent study has
demonstrated that the introduction of C-to-U mutations in the
trans-activation response (TAR) element, a key regulation factor
of HIV-1 transcription elongation, results in an early block of
viral gene expression (Nowarski et al., 2014) (Figure 1).
APOBEC3G-induced G-to-A hypermutations that block viral
replication have also been detected in the proviral genomes of
infected patients, probably because natural variants of Vif do not
completely neutralize A3G and other A3 family proteins (Janini
et al., 2001; Kieffer et al., 2005; Simon et al., 2005). Individuals
with low to undetectable plasma HIV-1 RNA levels, referred
to as “elite controllers,” have frequent G-to-A hypermutations
(Gandhi et al., 2008). Therefore, A3G is also presumably involved
in the production of defective viruses in vivo (Pace et al., 2006;
Armitage et al., 2012; Eyzaguirre et al., 2013; Krisko et al., 2013;
Sato et al., 2014; Delviks-Frankenberry et al., 2016). However,
the incomplete neutralization of A3 family proteins by Vif might
result in sequence diversification in vivo (Simon et al., 2005; Kim
et al., 2010, 2014; Sato et al., 2014; Alteri et al., 2015).
Degradation of Uracilated DNA
APOBEC3G, compared with catalytically inactive A3G, decreases
the copy number of reverse transcripts in the early phases of
infection (Anderson and Hope, 2008; Bishop et al., 2008). In
addition, before A3G was identified as a Vif-related cellular
factor, von Schwedler et al. (1993) had reported that levels
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FIGURE 1 | Proposed antiviral mechanisms of APOBEC3G (A3G) in vif-deficient HIV-1-infected cells. A3G potentially blocks several processes of
vif-deficient HIV-1 [vif (–) HIV-1] replication in a infected cell. (1) A3G interferes with the annealing of the tRNA primer for reverse transcription. (2) A3G physically
blocks reverse transcription elongation by binding to RNA and/or ssDNA templates, referred to as a “roadblock” mechanism. A3G oligomerization is closely
associated with the efficiency of this action. (3) A3G-induced C-to-U mutations trigger the degradation of reverse transcripts by cellular uracil DNA glycosylases
(UNG1, etc.). (3) Direct interaction of A3G with HIV-1 integrase blocks the formation of the replication-competent pre-integration DNA complex. (4) A3G decreases
the efficiency and specificity of tRNA primer removal, thereby producing a poor substrate for strand transfer and integration. (5) dC-to-dU conversions in viral
(–)ssDNA cause G-to-A hypermutations in progeny viral genomes, thereby leading to viral replication failure, called “error catastrophe.” In part, dC-to-dU mutations in
the trans-activation response (TAR) element result in an early block of HIV-1 transcription.
of the reverse transcripts of vif -deficient HIV-1 are decreased
in newly infected cells when the virus is produced from
non-permissive cell lines (currently known as cell lines expressing
high amounts of A3G). Thus, it was initially proposed that
A3G-induced C-to-U mutations in nascent reverse transcripts
might trigger the degradation of reverse transcripts by cellular
uracil DNA glycosylases (UDGs), such as nuclear UNG2
and SMUG1 (Harris et al., 2003) (Figure 1). The UDG-
mediated removal of uracil bases from reverse transcripts
might result in the digestion of DNA products at the abasic
site by apurinic/apyrimidinic endonuclease. One study further
supporting this possibility has shown that the antiviral activity
of A3G is partially affected by the UNG2 inhibitor (Ugi) and
siRNA specific to UNG2 in virus-producing cells but not in
target cells (Yang et al., 2007). However, other studies have
shown that UNG2 and SMUG1 are dispensable for the antiviral
activity of A3G: A3G-mediated antiviral activity is not changed
by Ugi expression (Kaiser and Emerman, 2006; Mbisa et al.,
2007; Langlois and Neuberger, 2008), and A3G activity has
been observed in Epstein-Barr virus-transformed B-cell lines
derived from a UNG2 –/– patient (Kaiser and Emerman, 2006)
and in a SMUG1-deficient avian cell line, with or without
exogenous Ugi expression (Langlois and Neuberger, 2008). More
recently, two studies have shown involvement of uracilated
vDNAs in their chromosomal integration during infection of
human cells that contain high levels of dUTP. Yan et al.
(2011) have reported that the uracilated vDNA protected it
from autointegration, which resulted in facilitating chromosomal
integration and viral replication. In contrast, the other study by
Hansen et al. (2016) indicated that heavily uracilated vDNAs
in monocyte-derived macrophages, not in T-lymphocytes, were
not efficiently integrated into chromosomal DNA due to
their UNG2-dependent degradation in the nucleus. These data
suggest different fate of uracilated vDNA between cytoplasm
and nucleus during HIV-1 infection. In addition, because the
deaminase-dependent antiviral mechanism has been observed
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in a variety of cell types, unidentified cellular factors might
determine the fate of vDNA containing A3G-induced uracil.
Therefore, additional studies are required to determine whether
other cellular uracil DNA repair enzymes beyond UNG2 and




Although A3G-mediated deamination was initially proposed to
be the sole mechanism of the antiviral activity against vif -
deficient HIV-1, subsequent studies have demonstrated that
other mechanisms are also involved in the inhibition of viral
replication. In addition, the enzymatic activity of A3F is not
absolutely required for its inhibitory effect on vif -deficient HIV-
1 replication (Holmes et al., 2007; Luo et al., 2007; Mbisa et al.,
2010). Furthermore, a deaminase activity-deficient A3G mutant
blocks the replication of HIV-1, mouse mammary tumor virus,
and murine leukemia virus, to a certain extent (Okeoma et al.,
2007; Belanger et al., 2013), thus suggesting the broad specificity
of antiviral activity in terms of the deaminase-independent
mechanism.
Initially, Guo et al. (2006, 2007) suggested that A3G might
interfere with tRNALys3 primer placement in viral reverse
transcription, in a manner independent of A3G-mediated
deamination (Figure 1). However, such inhibition of primer
annealing has not been observed in other studies (Iwatani et al.,
2007; Bishop et al., 2008). Instead, the inhibition of HIV-1 RT
elongation has been demonstrated by using in vitro and in vivo
systems (Iwatani et al., 2007; Bishop et al., 2008; Adolph et al.,
2013; Belanger et al., 2013) (Figure 1). It has been suggested that
the inhibitory effect reflects the following unique biochemical
characteristics of A3G: (1) A3G protein exhibits high affinity
binding specifically to single-stranded polynucleotides, such as
ssDNA and RNA (Iwatani et al., 2006; Polevoda et al., 2015);
(2) A3G, compared with RT, exhibits significantly higher binding
affinity for polynucleotides, although A3G shows similar or
slightly less binding affinity for ssDNA than the NC (Iwatani
et al., 2006; Darlix et al., 2011); (3) A3G mediates homo-
oligomerization in a dose-dependent manner in the presence of
ssDNA or RNA, whereas A3G forms monomers, dimers, and
tetramers in the absence of these polynucleotides (Wedekind
et al., 2006; Salter et al., 2009); and (4) A3G initially binds ssDNA
with rapid on-off rates and subsequently converts to a slow
dissociation mode after homo-oligomerization (Chaurasiya et al.,
2014). Therefore, A3G probably inhibits reverse transcription
by tightly binding to the ssDNA or RNA template, thus
forming a roadblock that physically obstructs viral DNA synthesis
(Iwatani et al., 2007; Adolph et al., 2013; Chaurasiya et al.,
2014) (Figure 1). This deaminase-independent mechanism
might increase the availability of ssDNA for deamination by
A3G (Adolph et al., 2013; Chaurasiya et al., 2014), thereby
resulting in cooperative effects between deaminase-dependent
and deaminase-independent mechanisms.
A3G-mediated inhibition of plus-strand DNA transfer and
integration has also been observed (Mbisa et al., 2007, 2010)
(Figure 1). A3G decreases the efficiency and specificity of
tRNA processing and removal during reverse transcription,
thereby producing aberrant viral DNA ends defective for efficient
plus-strand transfer and integration. Interestingly, it has been
reported that A3F exerts an inhibitory effect on viral DNA
integration, although its mechanism differs from that of A3G;
A3F prevents integration by its binding to the double-stranded
DNA of the proviral DNA ends (Mbisa et al., 2010). In contrast
to the competition of nucleic acid interactions between A3G
and RT/integrase, direct interactions of the A3G protein with
HIV-1 RT (Wang et al., 2012) or integrase (Luo et al., 2007)
(Figure 1) have been reported to be a deaminase-independent
mechanism, although the molecular mechanism underlying the
specific affinity of A3G for a variety of retroviral RTs and
integrases remains unclear. This may be associated with a loss of
the reverse transcription complex structure in newly infected cells
when A3G coexists with RT (Carr et al., 2006).
Structural Basis of Antiviral Mechanisms
Recent progress in determining the A3G protein structure has
enhanced the current understanding of A3G-mediated antiviral
mechanisms, particularly interactions between nucleotides and
A3G. First, three-dimensional structures of the A3G CTD
were determined by using NMR spectroscopy (Chen et al.,
2008; Furukawa et al., 2009; Harjes et al., 2009) and X-ray
crystallography (Holden et al., 2008; Shandilya et al., 2010;
Li et al., 2012; Lu et al., 2015). Although the structure of
the A3G CTD/ssDNA complex has not yet been determined
experimentally, four different structural models of the ssDNA-
bound A3G CTD have been proposed to explain how A3G
recognizes the ssDNA substrate. The first ssDNA-bound model
shows the nearly vertical orientation of ssDNA relative to
helices α2 and α3 of the A3G CTD along a cleft around the
Zn-coordination center (Zn-center pocket; “brim” model) (Chen
et al., 2008). The second model suggests that ssDNA binds to the
Zn-center pocket with the ssDNA crossed over the cleft seen in
the brim model (“kinked” model; Holden et al., 2008). The third
model resembles the brim model, although in this model, helices
α2 and α3 are involved in ssDNA binding to a greater extent
(“straight” model; Furukawa et al., 2009). The recently proposed
fourth model based on the crystal structure of the A3G CTD-
CTD dimer is a hybrid model of the kinked and brim models (Lu
et al., 2015). Nevertheless, it remains inconclusive which ssDNA
substrate-binding model is appropriate for deamination catalysis.
Structures of the highly insoluble A3G NTD protein have
recently been determined by using NMR spectroscopy (Kouno
et al., 2015) and X-ray crystallography (Xiao et al., 2016).
The crystal structure of the A3G NTD, derived from the
rhesus macaque (Macaca mulatta) protein, reveals a detailed
structural mechanism illustrating A3G dimerization and the
interaction between the A3G NTD and ssDNA (Xiao et al.,
2016). The structural data suggest that ssDNA binding to the
A3G NTD changes the conformation of the loops around the
Zn-center pocket and Y124 in loop7, thus functioning as a
“molecular switch” that regulates the opened/closed status of
the Zn-center pocket. The structure also indicates that the
dimerization interfaces of the A3G NTD dimer provide a
large positively charged surface, including the Zn-center pocket,
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FIGURE 2 | APOBEC3G domain structures important for the antiviral activities. (A) Schematics of the A3G domain primary sequence and the domain
structures are shown in the Upper and Lower, respectively. Zn-coordination motifs and the main DNA/RNA binding sites surrounding Zn are blue and red,
respectively. (B) The surface representation of the DNA/RNA binding site in the absence (Left) or presence (Right) of a ssDNA substrate. (C) Structure of the rhesus
A3G-NTD dimer (Left) and key residues involved in dimerization interfaces (Right).
thereby resulting in the formation of a high affinity surface
toward the ssDNA or RNA (Figure 2). These structural features
are consistent with results of previous biochemical studies
suggesting that the NTD-NTD interaction is crucial for A3G
oligomerization, nucleic acid binding, and the antiviral activity
of A3G (Bennett et al., 2008; Huthoff et al., 2009; Chelico et al.,
2010; Shandilya et al., 2010; Belanger et al., 2013; Chaurasiya et al.,
2014).
CONCLUSION
Recent evidence suggests that A3G executes potent antiviral
activity through cooperative deaminase-dependent and
deaminase-independent mechanisms. Undoubtedly, the
enzymatic activity of A3G is closely correlated with the potential
to inhibit vif -deficient HIV-1 replication. However, it remains
unclear how the A3G-mediated deamination event is linked to
the A3G-mediated lethal inhibition of viral replication. Further
studies of the molecular mechanisms of A3G antiviral activity,
particularly for the deaminase-dependent mechanisms, are
required, including the careful determination of the fate of
uracil-containing viral DNA in newly HIV-1-infected cells.
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